ESMO Gastrointestinal Cancers Congress | Conference

Dr. Conroy Discusses Survival Data With FOLFIRINOX in Pancreatic Cancer

June 20th 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX in pancreatic cancer.

Dr. Finn Discusses the Pooled Analysis of REACH and REACH-2 in HCC

June 20th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

January 8th 2018

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

Dr. Modest on Study of Surgical Intervention in CRC

July 6th 2017

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer

July 6th 2017

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction cancer.

Biomarker Analysis Identifies Prognostic Markers for Aflibercept Efficacy in CRC

July 6th 2017

Ziv-aflibercept (Zaltrap) prolonged overall survival compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated RAS, KRAS, and BRAF genes.

CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT

July 6th 2017

While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.

Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

July 5th 2017

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

Dr. O'Neil Discusses Napabucasin With FOLFIRI and Bevacizumab in CRC

July 5th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses napabucasin with FOLFIRI and bevacizumab (Avastin) in colorectal cancer.

Expert Discusses Surgical Intervention in Metastatic CRC

July 2nd 2017

In a central evaluation for surgical treatment options in the FIRE-3 study results, investigators set out to determine the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.

Dr. Lenz Discusses Immunotherapy in Gastrointestinal Cancers

July 1st 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.

Dr. Schmoll Discusses CHARTA Results in CRC

July 1st 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.

Napabucasin Clinically Active in Both Pancreatic and Colon Cancer

July 1st 2017

The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.

Novel Bispecific Antibody Effective for Heavily Pretreated mCRC

July 1st 2017

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

Liquid Biopsies Identify Mechanisms of Resistance in Gastrointestinal Cancers

July 1st 2017

Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.

Occurrence of Hand-Foot Skin Response May Signal Regorafenib Activity in Hepatocellular Carcinoma

June 30th 2017

Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.

Advanced Age Presents No Barrier to Successful Nivolumab Treatment in HCC

June 30th 2017

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma

June 30th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

Dr. Parikh Discusses Liquid Biopsies in Gastrointestinal Cancers

June 30th 2017

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.

Expert Discusses Tumor Location and Mutational Status in CRC

June 30th 2017

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.